Abstract:Chagas disease is a zoonosis caused by the protozoan parasite Trypanosoma cruzi . Clinical outcomes range from long-term asymptomatic carriage to cardiac, digestive, neurological and composite presentations that can be fatal in both acute and chronic stages of the disease. Studies of T . cruzi in animal models, principally mice, have informed our understanding of the biological basis of this variability and its relationship to infection and host response dynamics. Hamsters have higher translational value for many human infectious diseases, but they have not been well developed as models of Chagas disease. We transposed a real-time bioluminescence imaging system for T . cruzi infection from mice into female Syrian hamsters ( Mesocricetus auratus ). This enabled us to study chronic tissue pathology in the context of spatiotemporal infection dynamics. Acute infections were widely disseminated, whereas chronic infections were almost entirely restricted to the skin and subcutaneous adipose tissue. Neither cardiac nor digestive tract disease were reproducible features of the model. Skeletal muscle had only sporadic parasitism in the chronic phase, but nevertheless displayed significant inflammation and fibrosis, features also seen in mouse models. Whereas mice had normal locomotion, all chronically infected hamsters developed hindlimb muscle hypertonia and a gait dysfunction resembling spastic diplegia. With further development, this model may therefore prove valuable in studies of peripheral nervous system involvement in Chagas disease. Chagas disease is a caused by American trypanosomes ( Trypanosoma cruzi ). These are microscopic parasites that circulate in wild mammals across most of the Americas and can also be transmitted to humans. Much of our knowledge about how T . cruzi causes Chagas disease comes from studies of infections in mice, but the data do not capture the full range of clinical outcomes seen in humans. For many other pathogens the hamster has proved to be a valuable model of human infections. We therefore aimed to apply some of the latest advances in T . cruzi infection imaging technology to studies in this alternative experimental model. In the early stages, parasites were widely disseminated throughout the body, but after several months parasites became almost entirely restricted to the skin. Hamsters did not show signs of heart or gut disease, which are common in humans, but they did develop skeletal muscle pathology. Stiffness in the hindlimbs grew progressively worse and resulted in a visibly altered gait, suggestive of damage to the nervous system. With further development, this model may therefore prove valuable in studies of peripheral nervous system involvement in Chagas disease.

Animal models of Chagas disease and their translational value to drug development

Animal models for exploring Chagas disease pathogenesis and supporting drug discovery

Phenotypic screening approaches for Chagas disease drug discovery

Challenges in Chagas Disease Drug Development

What are the translational challenges associated with Chagas disease drug discovery?

Machine Learning Models and Pathway Genome Data Base for Trypanosoma cruzi Drug Discovery

High Throughput Screening for Anti–Trypanosoma cruzi Drug Discovery

A panel of phenotypically and genotypically diverse bioluminescent:fluorescent Trypanosoma cruzi strains as a resource for Chagas disease research

Discovery and Genetic Validation of Chemotherapeutic Targets for Chagas' Disease

Trypanosoma cruzi antigen detection in blood to assess treatment efficacy and cure in mice models of Chagas disease

Listen to what the animals say: a systematic review and meta-analysis of sterol 14-demethylase inhibitor efficacy for in vivo models of Trypanosoma cruzi infection

Repurposing strategies for Chagas disease therapy: the effect of imatinib and derivatives against Trypanosoma cruzi

4-aminopyridyl-based lead compounds targeting CYP51 prevent spontaneous parasite relapse in a chronic model and improve cardiac pathology in an acute model of Trypanosoma cruzi infection

A panel of phenotypically and genotypically diverse bioluminescent:fluorescent strains as a resource for Chagas disease research

Challenges and advancements in the development of vaccines and therapies against Chagas disease

Repositioning FDA Drugs as Potential Cruzain Inhibitors from Trypanosoma cruzi: Virtual Screening, In Vitro and In Vivo Studies

Treatment options for Chagas Disease: a systematic review and meta-analysis applied to the preclinical studies using animal models

Alternative Approaches for the Treatment of Chagas Disease

Anti-trypanosomatid drug discovery: progress and challenges

Dynamics of Trypanosoma cruzi infection in hamsters and novel association with progressive motor dysfunction

Tackling the Challenges of human Chagas Disease: a Comprehensive Review of Treatment Strategies in the Chronic Phase and Emerging Therapeutic Approaches